Hereditary Angioedema Clinical Trials

A listing of Hereditary Angioedema medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
Featured trial
HAE - Patients diagnosed with Acute Hereditary Angioedema

HAE - Patients diagnosed with Acute Hereditary Angioedema

  • 735 views
  • 08 Nov, 2020
  • 1 location
OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

The purpose of this study is to evaluate the safety and efficacy of donidalorsen in participants with HAE and effect of donidalorsenon the quality and pattern of HAE attacks and their impact on quality of life (QoL).

angioedema
  • 1 views
  • 11 Jul, 2022
  • 16 locations
A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II (KVD824-201)

A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.

  • 0 views
  • 22 Jul, 2022
  • 32 locations
NTLA-2002 in Adults With Hereditary Angioedema (HAE) (NTLA-2002)

This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).

angioedema
  • 0 views
  • 26 Jul, 2022
  • 3 locations
A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

This study is a randomized, double-blind, placebo-controlled, phase III, three-way crossover clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary

angioedema
c1 inhibitor (human)
  • 4 views
  • 13 Jul, 2022
  • 15 locations
A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

The main aim of this study is to evaluate the safety of lanadelumab in Chinese participants with HAE. Participants will be treated with a subcutaneous injection of lanadelumab every two weeks for 26 weeks. During the study, each participant will make 16 visits to study clinics.

  • 0 views
  • 27 Jul, 2022
  • 4 locations
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).

  • 0 views
  • 09 Aug, 2022
Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS) (LANA-FXII)

This is a Phase 2, exploratory, proof-of-concept, single-center, open-label pilot study to assess the effects and safety of Lanadelumab in patients with FXII-associated cold autoinflammatory syndrome (FACAS).

  • 0 views
  • 25 Mar, 2022
  • 1 location
Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (RAPIDe-1)

This study evaluates the efficacy of orally administered PHA-022121 for the acute treatment of attacks in patients with hereditary angioedema (HAE). Eligible subjects are randomized to one of

angioedema
  • 4 views
  • 07 Mar, 2022
  • 35 locations
Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II (HAE CHAPTER-1)

This study evaluates the safety and efficacy of PHA-022121 administered orally for prophylaxis against angioedema attacks in patients with hereditary angioedema (HAE). The study will have 3

hereditary angioedema type i
angioedema
  • 0 views
  • 23 Jul, 2022
  • 20 locations